

Effectiveness of a sildenafil citrate suspension for pulmonary hypertension in children: a randomised pragmatic trial

Submission date 30/01/2008	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 09/05/2008	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 09/05/2008	Condition category Circulatory System	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Gisele Huf

Contact details

National Institute of Quality Control in Health
Oswaldo Cruz Foundation
Av. Brasil 4365
Manguinhos
Rio de Janeiro
Brazil
21040-900

Additional identifiers

Study information

Scientific Title

Sildenafil citrate suspension versus sildenafil citrate powder paper for reduction of pulmonary hypertension in children during cardiac catheterisation: a randomised pragmatic trial

Study objectives

In Brazil, sildenafil citrate is the most accessible option for the treatment of PH and it is widely used in most hospitals. When licensing sildenafil for treatment of PH, the regulating agency kept it forbidden for people under 18 years old. In the absence of an appropriate pharmaceutical formulation for children, the staff usually crush the tablets to be added to liquid food. However, modifying a commercially available medication may lead to increased toxicity, undesirable side effects, decreased efficacy, poor patient compliance because of the medications taste and potential hazards to health care workers. Our study hypothesis is that a compounding suspension made by a pharmacist in controlled conditions will do better than the powder papers used in routine.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The project was submitted to the Ethics Committee of the Oswaldo Cruz Foundation (ref: CAAE - 0068.0.011.000-07) and will also be submitted to the Ethics Committee of every participating hospital.

Study design

Randomised pragmatic double-blind multicentre trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Pulmonary hypertension

Interventions

Power calculations:

60% of patients reduce at least 20% the mean pulmonary arterial pressure after using powder papers of Sildenafil citrate (SC). To demonstrate that at least 80% of patients would present 20% reduction after using SC suspension with an alpha error of 5% and power of 80% it would be necessary to recruit 182 patients. The pilot intends to recruit 20 patients.

Disease information:

Pulmonary hypertension (PH) is a haemodynamic and clinic disease characterised by a progressive increase of pulmonary vascular resistance and a decrease of pulmonary vascular capacitance leading to right ventricular failure and death. It may occur in isolation (idiopathic pulmonary arterial hypertension) or it may be associated to a variety of systemic disorders (scleroderma, lupus, human immunodeficiency virus [HIV] infection) or cardiopulmonary pathologies such as congenital heart disease. PH is a rare condition and secondary pulmonary arterial hypertension prevalence is less than 0.0001% (statistics about secondary pulmonary hypertension, 2007). Although severe pulmonary arterial hypertension is uncommon, the prognosis of these patients is life threatening and treatment options are limited.

Interventions:

A sildenafil citrate suspension developed from the crushed tablets will be compared with the powder papers usually given to the children.

1. Sildenafil citrate suspension: the suspension will be prepared from both commercially available tablets and sildenafil citrate powder and the formulation must be easy to prepare at hospital pharmacies. The physical, chemical and microbiology stability of this suspension will be assessed simulating in-use conditions and the ones established by Brazilian drug laws.
2. Sildenafil citrate powder papers: the powder papers will be prepared from the crushed commercial tablets and addition of a diluent. The tablets will be sent to a private pharmacy to compound sildenafil citrate 5 mg powder papers (sachets) as its already done as a routine.

Both arms will receive sildenafil citrate 0.2 mg/kg as a single dose during cardiac catheterisation.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Sildenafil citrate (SC)

Primary outcome(s)

The proportion of patients in each group that reduce pulmonary arterial hypertension in at least 20% twenty minutes after the administration of sildenafil citrate 0.2 mg/kg, during cardiac catheterisation.

Key secondary outcome(s)

1. At 20 minutes measured by cardiac catheterisation after administration of sildenafil citrate:
 - 1.1. Pulmonary vascular resistance
 - 1.2. Pulmonary vascular resistance/systemic vascular resistance
 - 1.3. Oxygenation index or oxygen requirement
 - 1.4. Cardiac output
 - 1.5. Mean systemic arterial pressure and surgery indication based on the response to sildenafil
2. At 24 hours: any adverse events
3. At 2 months: cardiac surgery and death

Completion date

01/11/2008

Eligibility

Key inclusion criteria

1. Children from 0 to 18 years old, either sex
2. Diagnosed as having PH associated with congenital heart disease
3. Needing cardiac catheterisation with sildenafil to evaluate the response to the drug as a decision criteria to cardiac surgery

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Lower age limit

0 years

Upper age limit

18 years

Sex

All

Key exclusion criteria

Children will be excluded if:

1. The clinician believes that sildenafil represents an additional risk for the patient
2. The carrier refuses to sign the informed consent

Date of first enrolment

01/05/2008

Date of final enrolment

01/11/2008

Locations**Countries of recruitment**

Brazil

Study participating centre

National Institute of Quality Control in Health

Rio de Janeiro

Brazil

21040-900

Sponsor information**Organisation**

National Institute of Quality Control in Health - Oswaldo Cruz Foundation (Brazil)

ROR

<https://ror.org/04jhswv08>

Funder(s)

Funder type

Research organisation

Funder Name

Oswaldo Cruz Foundation (Brazil)

Funder Name

National Institute of Cardiology (Brazil)

Funder Name

Pharmaceutical Industrial Technology Lab from Federal University of Rio de Janeiro (Brazil)

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration